IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 276-300 out of 1213.

<< < 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 > >>

Public Release: 11-Dec-2014
San Antonio Breast Cancer Symposium
Lancet Oncology
New evidence reveals tamoxifen reduces breast cancer rates by nearly a third for 20 years
The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years -- with rates reduced by around 30 percent -- new analysis published in The Lancet Oncology reveals.
Cancer Research UK

Contact: Charli Scouller
c.scouller@qmul.ac.uk
020-788-27943
Queen Mary, University of London

Public Release: 11-Dec-2014
Medical Care
Early adoption of robotic surgery leads to organ preservation for kidney cancer patients
Researchers at NYU Langone Medical Center conclude that patients with operable kidney tumors were more likely to undergo a partial nephrectomy -- the recommended course of treatment -- at hospitals that were early adopters of robotic surgery.

Contact: Jim Mandler
jim.mandler@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine

Public Release: 11-Dec-2014
Developmental Cell
Senescent cells play an essential role in wound healing
Tumor suppressing senescent cells are bad for aging. The no-longer-dividing cells release a continual cascade of inflammatory factors and are implicated in many maladies including arthritis, atherosclerosis and late life cancer. But researchers show that senescent cells are good for wound healing -- identifying a single factor that causes them to promote that process. It's a crucial discovery for researchers working on developing treatments to clear senescent cells as a way to stem age-related disease.
American Italian Cancer Foundation, Japan Science and Technology Agency, National Institutes of Health, European Council

Contact: Kris Rebillot
krebillot@buckinstitute.org
415-209-2080
Buck Institute for Age Research

Public Release: 11-Dec-2014
Cell
3-D maps reveal the genome's origami code
In a triumph for cell biology, researchers have assembled the first high-resolution, 3-D maps of entire folded genomes and found a structural basis for gene regulation -- a kind of 'genomic origami' that allows the same genome to produce different types of cells. The research appears online today in Cell.
National Science Foundation, National Institutes of Health, NIH/National Human Genome Research Institute, NVIDIA, IBM, Google, Cancer Prevention and Research Institute of Texas, McNair Medical Institute

Contact: Jade Boyd
jadeboyd@rice.edu
713-348-6778
Rice University

Public Release: 11-Dec-2014
Cancer Cell
New targeted drugs could treat drug-resistant skin cancer
A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports. Clinical trials to test the new drugs in patients should begin as early as 2015.
Wellcome Trust, Cancer Research UK

Contact: Clare Ryan
c.ryan@wellcome.ac.uk
020-761-17262
Wellcome Trust

Public Release: 11-Dec-2014
American Journal of Epidemiology
Human exposure to metal cadmium may accelerate cellular aging
A new study led by a researcher at Milken Institute School of Public Health at the George Washington University looks at the metal cadmium and finds that higher human exposure can lead to significantly shorter telomeres, bits of DNA at the ends of chromosomes that are associated with cardiovascular disease, diabetes and other diseases of old age.

Contact: Kathy Fackelmann
kfackelmann@gwu.edu
202-994-8354
George Washington University Milken Institute School of Public Health

Public Release: 11-Dec-2014
Cancer Cell
Getting antibodies into shape to fight cancer
Scientists at the University of Southampton have found that the precise shape of an antibody makes a big difference to how it can stimulate the body's immune system to fight cancer, paving the way for much more effective treatments.
Cancer Research UK

Contact: Becky Attwood
r.attwood@soton.ac.uk
University of Southampton

Public Release: 11-Dec-2014
Bioinformatics
WPI team develops tool to better classify tumor cells for personalized cancer treatments
A new statistical model developed by a research team at Worcester Polytechnic Institute may enable physicians to create personalized cancer treatments for patients based on the specific genetic mutations found in their tumors. The model uses an advanced algorithm to identify the multiple genetic cell subtypes typically found in solid tumors by analyzing gene expression data from a small biopsy sample. The results can help shape more effective treatments and also guide future research.

Contact: Michael Cohen
mcohen@wpi.edu
508-868-4778
Worcester Polytechnic Institute

Public Release: 11-Dec-2014
Medical Care
Surgical robot adopters use more of recommended procedure for kidney cancer, reports Medical Care
Hospitals with robotic surgical systems are more likely to perform 'nephron-sparing' partial nephrectomy -- a recommended alternative to removal of the entire kidney -- in patients with kidney cancer, reports a study in the December issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 11-Dec-2014
Journal of Biomedical Nanotechnology
'Trojan horse' proteins used to target hard-to-reach cancers
Scientists at Brunel University London have found a way of targeting hard-to-reach cancers and degenerative diseases using nanoparticles, but without causing the damaging side effects the treatment normally brings.

Contact: Keith Coles
keith.coles@brunel.ac.uk
Brunel University

Public Release: 11-Dec-2014
San Antonio Breast Cancer Symposium
Three San Antonio studies target androgen in breast cancer
Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 10-Dec-2014
JAMA
Many breast cancer surgery patients do not receive shorter radiation treatment
Although the use of a type of radiation treatment that is shorter in duration and less costly has increased among women with early-stage breast cancer who had breast conserving surgery, most patients who meet guidelines to receive this treatment do not, according to a study appearing in JAMA. The study is being released to coincide with the San Antonio Breast Cancer Symposium.

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-349-5653
The JAMA Network Journals

Public Release: 10-Dec-2014
Molecular Oncology
New breast cancer classification based on epigenetics
Breast cancer is the most common in women. One in nine will suffer breast cancer over their lifetime. Progress in prevention and early detection, and the use of chemotherapy after surgery (adjuvant chemotherapy), have achieved significantly increase survival in this disease in the last ten years, but much remains to be done.
Icelandic Centre for Research, CellexFoundation

Contact: Arantxa Mena
amena@idibell.cat
0034-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 10-Dec-2014
Science Translational Medicine
Targeting mitochondrial enzyme may reduce chemotherapy drug's cardiac side effects
Massachusetts General Hospital investigators have identified two compounds that appear, in cellular and animal models, to block the cardiac damage caused by the important chemotherapy drug doxorubicin without reducing its anti-tumor effects.
American Heart Association

Contact: Cassandra Aviles
cmaviles@partners.org
617-724-6433
Massachusetts General Hospital

Public Release: 10-Dec-2014
JAMA
Most women with early-stage breast cancer in US receive radiation for too long
Two-thirds of women treated for early-stage breast cancer in the US receive longer radiation therapy than necessary, according to a new study published in JAMA this week from Penn Medicine researchers Ezekiel J. Emanuel, M.D., Ph.D., and Justin E. Bekelman, M.D.
Anthem, Inc., NIH/National Cancer Institute

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine

Public Release: 10-Dec-2014
Nature
Molecular tag team revealed to control cell division
Manchester scientists have explored the role of three molecules in controlling the process of cell division in a bid to gain new insight into the transmission of vital signals from a cell's exterior to its interior.
Cancer Research UK

Contact: Jamie Brown
Jamie.brown@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
German breast group study: Superior activity for nab-paclitaxel in early breast cancer
German Breast Group Ph III study demonstrates superior activity for nab-paclitxel vs conventional paclitaxel in early, high-risk breast cancer, and utility of pCR (pathological complete response) as a surrogate marker for long-term efficacy

Contact: Peggy C. Frank
pfrank@frankpr.com
818-642-6804
Initiate PR

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer
A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker -- the quantity of tumor-infiltrating lymphocytes in a biopsy -- appears irrelevant when trastuzumab is used.
Mayo Clinic, Donna Foundation, Breast Cancer Research Foundation, NIH/National Cancer Institute, Alliance for Clinical Trials in Oncology, North Central Cancer Treatment Group

Contact: Paul Scotti
scotti.paul@mayo.edu
904-953-0199
Mayo Clinic

Public Release: 10-Dec-2014
Chemical Research in Toxicology
New technology tracks carcinogens as they move through the body
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
Public Health Service, US Department of Energy, NIH/National Institute of General Medical Sciences

Contact: David Williams
david.williams@oregonstate.edu
541-737-3277
Oregon State University

Public Release: 10-Dec-2014
Journal of Cardiac Failure
NYIT study: Thyroid hormones reduce animal cardiac arrhythmias
Rats that received thyroid hormones had a reduced risk for dangerous heart arrhythmias following a heart attack, according to a new study by a team of medical researchers at New York Institute of Technology. In the National Institutes of Health-funded study, published in the Journal of Cardiac Failure, the team found that thyroid hormone replacement therapy significantly reduced the incidence of atrial fibrillation -- a specific kind of irregular heartbeat, or arrhythmia -- in the rats, compared to a control group that did not receive the hormones.
National Institutes of Health

Contact: Elaine Iandoli
eiandoli@nyit.edu
516-223-5935
New York Institute of Technology

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
Novel approach for estrogen-receptor-positive breast cancer reported
Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.

Contact: Nora Dudley
nodudley@lumc.edu
708-216-6268
Loyola University Health System

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
New drug combination for advanced breast cancer delays disease progression
A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study were presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 6-9, by Kerin Adelson, M.D., assistant professor of medical oncology at Yale Cancer Center and chief quality officer at Smilow Cancer Hospital at Yale-New Haven.
NIH/National Cancer Institute, Millenium, Takeda Oncology Company

Contact: Vicky Agnew
Vicky.agnew@yale.edu
843-697-6208
Yale University

Public Release: 10-Dec-2014
San Antonio Breast Cancer Symposium
Pathway that degrades holiday turkey fuels metastasis of triple negative breast cancer
A University of Colorado Cancer Center study being presented at the San Antonio Breast Cancer Symposium shows that triple negative breast cancer cells process tryptophan to promote survival while traveling through the body in order to seed new tumor sites.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 10-Dec-2014
Proceedings of the National Academy of Sciences
Testosterone may contribute to colon cancer tumor growth
James Amos-Landgraf, an assistant professor of veterinary pathobiology in the MU College of Veterinary Medicine, found evidence suggesting that the male hormone testosterone may actually be a contributing factor in the formation of colon cancer tumors.
National Institutes of Health, American Cancer Society

Contact: Nathan Hurst
hurstn@missouri.edu
573-882-6217
University of Missouri-Columbia

Public Release: 10-Dec-2014
Nature Communications
New insight into cancer defense mechanism
Researchers at the University of Copenhagen have identified a new mechanism which gives a better understanding of cancer development. The results have just been published in the scientific journal Nature Communications.

Contact: Jakob Nilsson
jakob.nilsson@cpr.ku.dk
45-35-32-50-53
University of Copenhagen - The Faculty of Health and Medical Sciences

Showing releases 276-300 out of 1213.

<< < 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 > >>

  Search News Releases

     

 

EurekAlert!